PIERCE1 and lung carcinoma: To further confirm our findings, an allograft of a mutant KRAS expressing lung cancer cell line (LL/2) was subcutaneously introduced into the flank regions of C57BL6/J mice and siRNA against PIERCE1 was administered into tumor mass every three days (Supplementary Fig. 16a).